Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
² West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China.

Published Erratum

Jianyu Liu et al. Front Pharmacol. 2022.

. 2022 Sep 27:13:1000887.

doi: 10.3389/fphar.2022.1000887. eCollection 2022.

¹ State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
² West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.811682.].

Keywords: UCP3; heart failure; honokiol; myocardial infarction; reactive oxygen species.

Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition.
Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H, Chen L. Liu J, et al. Front Pharmacol. 2022 Feb 21;13:811682. doi: 10.3389/fphar.2022.811682. eCollection 2022. Front Pharmacol. 2022. PMID: 35264952 Free PMC article.